Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This clinical trial is a multicenter, randomized, open-label, phase-II study to evaluate the
efficacy and safety of maintenance treatment with eribulin mesylate following standard
adjuvant chemotherapy in triple negative breast cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University